Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy

Sleep

Volumn 33, Issue 10, 2010, Pages 1295-1304

  Burgess, Christian R ^a   Tse, Gavin ^a   Gillis, Lauren ^a   Peever, John H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cataplexy; Dopamine; Hypocretin orexin; Narcolepsy; Sleep

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; QUINPIROLE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATAPLEXY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG MEGADOSE; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; KNOCKOUT MOUSE; LOW DRUG DOSE; MALE; MOUSE; NARCOLEPSY; NONHUMAN; PRIORITY JOURNAL; SLEEP; SLEEP WAKING CYCLE; WILD TYPE;

EID: 78649878872     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/33.10.1295     Document Type: Article

References (63)

1. Siegel JM, Boehmer LN. Narcolepsy and the hypocretin system - where motion meets emotion. Nat Clin Pract Neurol 2006;2:548-56.
2. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7.
3. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74.
4. Thannickal TC, Siegel JM, Nienhuis R, Moore RY. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 2003;13:340-51.
5. Eisensehr I, Linke R, Tatsch K, et al. Alteration of the striatal dopaminergic system in human narcolepsy. Neurology 2003;60:1817-9. (Pubitemid 36737080)
6. Rissling I, Geller F, Bandmann O, et al. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks". Mov Disord 2004;19:1279-84.
7. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007;130:1586-95.
8. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-94.
9. Schmidt-Mutter C, Muller C, Zwiller J, Gobaille S, Maitre M. Gamma-hydroxybutyrate and cocaine administration increases mRNA expression of dopamine D1 and D2 receptors in rat brain. Neuropsychopharmacology 1999;21:662-9.
10. Howard SG, Feigenbaum JJ. Effect of gamma-hydroxybutyrate on central dopamine release in vivo. A microdialysis study in awake and anesthetized animals. Biochem Pharmacol 1997;53:103-10.
11. Monti JM, Hawkins M, Jantos H, D'Angelo L, Fernandez M. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacology (Berl) 1988;95:395-400.
12. Monti JM, Fernandez M, Jantos H. Sleep during acute dopamine D1 agonist SKF 38393 or D1 antagonist SCH 23390 administration in rats. Neuropsychopharmacology 1990;3:153-62.
13. Ongini E, Bonizzoni E, Ferri N, Milani S, Trampus M. Differential effects of dopamine D-1 and D-2 receptor antagonist antipsychotics on sleepwake patterns in the rat. J Pharmacol Exp Ther 1993;266:726-31.
14. Isaac SO, Berridge CW. Wake-promoting actions of dopamine D1 and D2 receptor stimulation. J Pharmacol Exp Ther 2003;307:386-94.
15. Bagetta G, De Sarro G, Priolo E, Nistico G. Ventral tegmental area: site through which dopamine D2-receptor agonists evoke behavioural and electrocortical sleep in rats. Br J Pharmacol 1988;95:860-6. (Pubitemid 18266264)
16. Honda K, Riehl J, Mignot E, Nishino S. Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep. Neuroreport 1999;10:3717-24.
17. Okura M, Fujiki N, Kita I, et al. The roles of midbrain and diencephalic dopamine cell groups in the regulation of cataplexy in narcoleptic Dobermans. Neurobiol Dis 2004;16:274-82.
18. Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel JM, Mignot E. Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. Brain Res 1996;733:83-100.
19. Lu J, Jhou TC, Saper CB. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 2006;26:193-202.
20. Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T, Scammell TE. Behavioral state instability in orexin knock-out mice. J Neurosci 2004;24:6291-300.
21. Thankachan S, Kaur S, Shiromani PJ. Activity of pontine neurons during sleep and cataplexy in hypocretin knock-out mice. J Neurosci 2009;29:1580-5.
22. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51.
23. Zarrindast MR, Tabatabai SA. Involvement of dopamine receptor subtypes in mouse thermoregulation. Psychopharmacology (Berl) 1992;107:341-6.
24. Ralph RJ, Caine SB. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther 2005;312:733-41.
25. Tirelli E, Witkin JM. Differential effects of direct and indirect dopamine agonists on the induction of gnawing in C57Bl/6J mice. J Pharmacol Exp Ther 1995;273:7-15.
26. Gessa GL, Porceddu ML, Collu M, et al. Sedation and sleep induced by high doses of apomorphine after blockade of D-1 receptors by SCH 23390. Eur J Pharmacol 1985;109:269-74.
27. Scammell TE, Willie JT, Guilleminault C, Siegel JM. A Consensus Definition of Cataplexy in Mouse Models of Narcolepsy. Sleep 2009;32.
28. Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 2004;13:395-406.
29. Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007;11:113-33.
30. Sharp T, Zetterstrom T, Ljungberg T, Ungerstedt U. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res 1987;401:322-30.
31. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;85:5274-8.
32. Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998;1:49-61.
33. Scammell TE, Matheson J. Modafinil: a novel stimulant for the treatment of narcolepsy. Expert Opin Investig Drugs 1998;7:99-112. (Pubitemid 28025489)
34. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995;18:817-26.
35. Rothman RB, Baumann MH. Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann N Y Acad Sci 2006;1074:245-60.
36. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003;38:715-30.
37. Nishino S, Arrigoni J, Valtier D, et al. Dopamine D2 mechanisms in canine narcolepsy. J Neurosci 1991;11:2666-71.
38. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-76.
39. Svensson K, Alfoldi P, Hajos M, et al. Dopamine autoreceptor antagonists: effects on sleep-wake activity in the rat. Pharmacol Biochem Behav 1987;26:123-9.
40. Westerink BH, De Boer P, Timmerman W, De Vries JB. In vivo evidence for the existence of autoreceptors on dopaminergic, serotonergic, and cholinergic neurons in the brain. Ann N Y Acad Sci 1990;604:492-504.
41. Olive MF, Seidel WF, Edgar DM. Compensatory sleep responses to wakefulness induced by the dopamine autoreceptor antagonist (-)DS121. J Pharmacol Exp Ther 1998;285:1073-83.
42. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl) 1993;113:76-82.
43. Nishino S, Tafti M, Reid MS, et al. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. J Neurosci 1995;15:4806-14.
44. Reid MS, Tafti M, Geary JN, et al. Cholinergic mechanisms in canine narcolepsy - I. Modulation of cataplexy via local drug administration into the pontine reticular formation. Neuroscience 1994;59:511-22.
45. Wu MF, Gulyani SA, Yau E, Mignot E, Phan B, Siegel JM. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 1999;91:1389-99.
46. Wu MF, John J, Boehmer LN, Yau D, Nguyen GB, Siegel JM. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J Physiol 2004;554:202-15.
47. Li Y, van den Pol AN. Direct and indirect inhibition by catecholamines of hypocretin/orexin neurons. J Neurosci 2005;25:173-83.
48. Yamanaka A, Muraki Y, Ichiki K, et al. Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner. J Neurophysiol 2006;96:284-98.
49. Willie JT, Renthal W, Chemelli RM, et al. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience 2005;130:983-95.
50. Monti JM, Jantos H, Fernandez M. Effects of the selective dopamine D-2 receptor agonist, quinpirole on sleep and wakefulness in the rat. Eur J Pharmacol 1989;169:61-6.
51. Okura M, Riehl J, Mignot E, Nishino S. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology 2000;23:528-38.
52. Burgess CR, Peever JH. Noradrenergic Modulation of Muscle Tone During Cataplexy in Hypocretin/Orexin Knockout Mice. Sleep 2009;32:A0052.
53. Nishino S, Riehl J, Hong J, Kwan M, Reid M, Mignot E. Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neurosci Res 2000;38:437-46.
54. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000;123 (Pt 6):1155-60.
55. Politis M, Piccini P, Pavese N, Koh SB, Brooks DJ. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo(11)C-raclopride PET study. Exp Neurol 2008.
56. Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007;130:2770-88.
57. Moller JC, Oertel WH. Pramipexole in the treatment of Parkinson's disease: new developments. Expert Rev Neurother 2005;5:581-6.
58. Schmidt MH, Koshal VB, Schmidt HS. Use of pramipexole in REM sleep behavior disorder: results from a case series. Sleep Med 2006;7:418-23.
59. McCormack PL, Siddiqui MA. Pramipexole: in restless legs syndrome. CNS Drugs 2007;21:429-37; discussion 38-40.
60. Keating GM, Raffin MJ. Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs 2005;19:785-803.
61. Tyne HL, Taylor J, Baker GA, Steiger MJ. Modafinil for Parkinson's disease fatigue. J Neurol 2009.
62. Black J, Guilleminault C. Medications for the treatment of narcolepsy. Expert Opin Emerg Drugs 2001;6:239-47.
63. Lingenhoehl K, Brom R, Heid J, et al. Gamma-hydroxybutyrate is a weak agonist at recombinant GABA(B) receptors. Neuropharmacology 1999;38:1667-73.